Literature DB >> 27485880

Idelalisib-induced pneumonitis.

Arjun Gupta1, Hsiao C Li2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27485880      PMCID: PMC4986151          DOI: 10.1136/bcr-2016-216343

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


× No keyword cloud information.
  1 in total

1.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

  1 in total
  3 in total

Review 1.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  An unusual case of Idelalisib-related pneumonitis with severe respiratory failure.

Authors:  Domingos Sousa; Maria Eduarda Couto; Alda Tavares; Teresa Ribeiro; Fabiana Santos Muñoz; Nelson Domingues; Isabel Oliveira; Mário Mariz
Journal:  EJHaem       Date:  2020-10-26

Review 3.  Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Authors:  Antonio Cuneo; Giovanni Barosi; Romano Danesi; Stefano Fagiuoli; Paolo Ghia; Alfredo Marzano; Marco Montillo; Venerino Poletti; Pierluigi Viale; Pier Luigi Zinzani
Journal:  Hematol Oncol       Date:  2018-09-05       Impact factor: 5.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.